BBlogFlow

Ipsos Health Service Report: Thailand’s Healthcare Landscape in 2026 - Ipsos

·Oct 9, 2026

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

The latest Ipsos Health Service Report 2026 highlights how public perceptions of healthcare are evolving around the world. Across 32 countries, people are increasingly focused on the quality, accessibility and future of healthcare systems, while mental health continues to gain recognition as an important component of overall wellbeing. For Thailand, the findings paint a picture of a healthcare system that is viewed positively by the public, while also reflecting broader shifts seen across Asia Pacific and globally. From mental health and healthcare access to population ageing and emerging innovations such as GLP-1 medications, the results provide valuable insight into how Thai consumers are thinking about health today and what they expect in the years ahead. Thailand ranks among the higher-performing healthcare systems globallyIpsos' Quality of Care Perception Index measures public perceptions across five dimensions: satisfaction with healthcare quality, trust in the healthcare system, access to doctors, access to pharmacies and perceptions of equitable care.

This article is an excerpt. To read the full content, visit the original source. Ipsos

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·